Verhoef, T I
Redekop, W K
Langenskiold, S
Kamali, F
Wadelius, M
Burnside, G
Maitland-van der Zee, A-H
Hughes, D A
Pirmohamed, M
Article History
Received: 12 October 2015
Revised: 19 April 2016
Accepted: 2 May 2016
First Online: 7 June 2016
Competing interests
: This work was supported by the European Community's Seventh Framework Programme under grant agreement HEALTH-F2-2009-223062. Dr Verhoef, Dr Maitland-van der Zee, Dr Wadelius and Dr Pirmohamed report grants from EU Commission FP7 programme, during the conduct of the study; Dr Wadelius reports grants from the Swedish Research Council (Medicine), grants from the Swedish Heart and Lung Foundation, grants from the Clinical Research Support at Uppsala University, during the conduct of the study; Dr Pirmohamed is an NIHR Senior Investigator; and as part of the EU-PACT trial, we worked with LGC (a UK-based company) who were a partner on the project, and developed the point-of-care platform which was used for genotyping in the trial, and on which the results of this cost-effectiveness paper are based. However, we did not receive any funding directly from LGC.